Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NAUTthis companyNautilus Biotechnolgy, Inc.	$2.35	-4.15×	1.57×	0×	-5.02×	-106.3%	0.0%	0.0%	0.0%	-37.6%	-35.7%	-21.1%	0.19×	-0.34×	0×	13.33×	0.0%	3	1.3	2	C
ARCTArcturus Therapeutics Holdings Inc.	$10.42	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
ASMBAssembly Biosciences, Inc.	$21.12	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
ENTAEnanta Pharmaceuticals, Inc.	$11.46	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
FHTXFoghorn Therapeutics Inc.	$1.98	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
HUMAHumacyte, Inc.	$0.48	-3.69×	48.86×	74.54×	-7.48×	-105.8%	-736.5%	-5271.7%	-2003.6%	-1313.4%	-107.0%	-69.7%	20.86×	-0.65×	-9.55×	3.69×	0.0%	3	-8.67	1	D+
Peer median	—	-3.69×	1.84×	5.27×	-5.99×	-382.4%	93.0%	-130.7%	-125.4%	-30.7%	-31.4%	-25.3%	0.12×	0.56×	0×	4.21×	0.0%	3	-0.92	2	—